HZNP News and Press, Horizon Therapeutics Public Limited Company From 04/04/23

Horizon Therapeutics plc (Nasdaq: HZNP) today announced that it has been named one of Fortune’s 100 Best Companies to Work For ® for the third consecutive year. “We are proud to be named to the Fortune 100 Best Companies to Work For list for the third time,&...

2023-04-03 04:12:14 ET Summary My portfolio, built specifically for my retirement ~20 years from now, features growth, dividends, and risk stocks for a happy retirement. Great performances by Bitcoin, AMD, and Meta propelled my portfolio to all-time highs and market-beating return...

2023-04-02 10:00:37 ET The deal spread in Pfizer's ( NYSE: PFE ) planned $43 billion purchase of Pfizer ( PFE ) is attractive with investors seeing decent upside upside from current levels, according to an Oppenheimer analyst. Seagen ( NASDAQ: SGEN ) is curre...

2023-03-24 05:18:59 ET Summary Amgen reported solid results for fiscal 2022 with the bottom line growing in the double digits. The company recently announced the acquisition of Horizon Therapeutics and while the acquisition might make sense it is increasing the total debt to rathe...

2023-03-21 15:29:32 ET Summary Horizon Therapeutics Public Limited Company is a $25 billion biotech that Amgen Inc. is acquiring. The FTC has issued a 2nd request. It doesn't seem likely this deal will ultimately get blocked. The spread is relatively wide, given I think th...

2023-03-16 14:15:32 ET Big pharma held steady on Thursday after the Centers for Medicare & Medicaid Services (CMS) issued initial guidance on the Medicare drug price negotiation program, which will go into effect in 2026. The program comes under President Biden's Inflation Reduc...

Horizon Therapeutics plc (Nasdaq: HZNP) today announced the presentation of new MRI imaging data from the Phase 3 clinical trial showing UPLIZNA reduced the formation of subclinical (asymptomatic) optic nerve lesions in people with NMOSD. These findings are being presented during the 49 th an...

2023-03-14 06:08:03 ET Summary Selecta Biosciences is a biotech firm working on therapies for rare illnesses. SEL-212, its lead product, helps control uric acid levels in chronic refractory gout patients. SEL-212 controls serum uric acid levels to treat chronic refractory gout by ...

2023-03-13 11:49:27 ET Amgen ( NASDAQ: AMGN ) traded higher Monday morning after Wells Fargo upgraded it, citing an opportunity following the company's ~$28B deal to acquire rare disease drugmaker Horizon Therapeutics ( HZNP ). "While we are not big fans of the HZNP de...

-- Data presented at the North American Neuro-Ophthalmology Society ( NANOS ) Annual Meeting on March 11-16 in Orlando -- Horizon Therapeutics plc (Nasdaq: HZNP) today announced results of an analysis of real-world treatment with TEPEZZA in Thyroid Eye Disease (TED) patients...